HCW Biologics (HCWB) CEO buys stock in private placement, may get warrants
Rhea-AI Filing Summary
HCW Biologics Inc. reports that CEO and 10% owner Hing C Wong purchased 23,210 shares of Common Stock at $2.585 per share in a private placement directly from the issuer under a July 29, 2026 Securities Purchase Agreement, bringing his direct holdings to 125,845 shares. Under the same agreement, he is entitled to common warrants exercisable for up to 23,210 additional shares, with issuance subject to stockholder approval under Nasdaq Listing Rule 5635(d); once issued, the warrants will be exercisable immediately and expire 5.5 years after issuance.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 23,210 shares
Net Buy
1 txn
Insider
Wong Hing C
Role
Chief Executive Officer
Bought
23,210 shs ($60K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1 | 23,210 | $2.585 | $60K |
Holdings After Transaction:
Common Stock — 125,845 shares (Direct)
Footnotes (1)
- F1. The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 23,210 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance.
Key Figures
Shares purchased: 23,210 shares
Purchase price: $2.585 per share
Total direct holdings: 125,845 shares
+2 more
5 metrics
Shares purchased
23,210 shares
Common Stock purchased on July 29, 2026
Purchase price
$2.585 per share
Price paid in private placement
Total direct holdings
125,845 shares
Direct Common Stock holdings following transaction
Potential warrant shares
23,210 shares
Aggregate shares underlying common warrants entitled under SPA
Warrant term
5.5 years
Common warrants expire 5.5 years from issuance and are immediately exercisable
Key Terms
private placement, Securities Purchase Agreement, Section 4(a)(2), Rule 506(b) of Regulation D, +2 more
6 terms
private placement financial
"purchased these shares directly from the issuer in a private placement under a SPA"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Securities Purchase Agreement regulatory
"purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Section 4(a)(2) regulatory
"purchase is exempt from registration requirements pursuant to Section 4(a)(2) thereof"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
Rule 506(b) of Regulation D regulatory
"and/or Rule 506(b) of Regulation D thereunder"
Rule 506(b) of Regulation D is a set of rules that allows companies to raise money from investors without having to register with the government, as long as they follow certain guidelines. It lets companies offer securities to a limited number of investors, often trusted or experienced ones, making it easier and quicker to raise funds compared to traditional methods. This rule matters to investors because it provides access to private investment opportunities that are generally less regulated but still require careful consideration.
Nasdaq Listing Rule 5635(d) regulatory
"issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d)"
Nasdaq Listing Rule 5635(d) is a stock-exchange rule that determines when a company must get shareholder approval before issuing new shares tied to conversions or exercises of existing convertible securities, options or warrants. It matters to investors because it controls potential dilution of their holdings and changes in voting power—think of it like a rule that decides whether a previously agreed‑upon coupon can be redeemed without asking the group again.
common warrants financial
"entitled to receive common warrants exercisable for an aggregate of up to 23,210 shares"
A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did HCW Biologics (HCWB) report for CEO Hing C Wong?
CEO Hing C Wong purchased 23,210 shares of HCW Biologics Common Stock at $2.585 per share. The shares were bought directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026.
Does the HCW Biologics (HCWB) CEO receive warrants as part of this transaction?
Yes. Under the Securities Purchase Agreement, the CEO is entitled to common warrants for up to 23,210 shares. Issuance of these warrants requires stockholder approval under Nasdaq Listing Rule 5635(d), after which they will be immediately exercisable and expire 5.5 years from issuance.
How is the HCW Biologics (HCWB) private placement transaction structured legally?
The CEO bought the shares directly from HCW Biologics in a private placement under a Securities Purchase Agreement dated July 29, 2026. The purchase is described as exempt from registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D.